In the HER2-driven model, A murine-based PK/PD model predicted tumor regression in patients after administration of 2 doses of trastuzumab - NMS-P945 - ADC at 0.5mg/kg, and observed high in vivo efficacy in cured mice at a well-tolerated dose. Here, ERBB2 is linked to neoplasm.